AAMU
TARO

Amundi Asset Management US’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Amundi Asset Management US’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-270
Closed -$27K – 1638
2018
Q1 		$27K Hold
270
– – ﹤0.01% 1504
2017
Q4 		$28K Buy
+270
New +$29.7K ﹤0.01% 1538

Other funds holding TARO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FL
Fort LP Chevy Chase, Maryland $39.6M AUM 37.11% 1-Year Est. Return

Amundi Asset Management US's TARO Position: Q2 2018 in Review

Amundi Asset Management US sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2018, closing a stake of 270 shares — an estimated $27K sold.

Amundi Asset Management US first reported a position in TARO in Q4 2017 and held it in 2 quarters. The position peaked at $28K in Q4 2017. 109 funds tracked by Wall St. Rank hold TARO as of Q2 2018.

  • Amundi Asset Management US reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 270 Taro Pharmaceutical Industries Ltd. shares in Q2 2018, an estimated $27K.
  • Amundi Asset Management US first reported a position in Taro Pharmaceutical Industries Ltd. in Q4 2017 and held it in 2 quarters.
  • Amundi Asset Management US's Taro Pharmaceutical Industries Ltd. position peaked at $28K in Q4 2017.
  • 109 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2018.

Based on Amundi Asset Management US's 13F filing for Q2 2018, filed 13 Aug 2018.